New Approach Targets Type 2’s Poorly Controlled With Metformin
Add-on of saxagliptin plus dapagliflozin shows greater improvements in glycemic control versus the use of single drug with metformin
-
-
Recent Posts
-
-
Drugs
Yohimbine Found Effective in Treating TII Diabetes Brought on by Stress
A new treatment for patients with type 2 diabetes could be on the horizon. Researchers recently discovered that Yohimbin, a medication that spent several years in de-registered status, is actually successful at blocking the damaging effects of gene variants that inhibit insulin production. If it becomes a clinical drug, personalized treatment may finally be available […]
Diabetes Self-Management – Type 1 Diabetes Cured in Mice — People and Type 2 Next?
A generic blood pressure medicine healed beta cells, curing diabetes in mice. Scientists are now recruiting for a human study to see if it works in people. It might heal both Type 1 and Type 2. The drug is called verapamil. It costs $4 a month at Walmart. It has been used for high blood […]
BattleDiabetes – Blood pressure drug completely reverses diabetes in animal models
A common blood pressure drug, verapamil, was shown to completely reverse diabetes in animal models, according to research from the University of Alabama at Birmingham.
DPP-4 Inhibitors in Combination with Insulin Therapy for Type 2 Diabetes Patients
Currently approved dipeptidyl peptidase-4 (DPP-4) inhibitors include alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin. DPP-4 inhibitors work by enhancing glucose dependent insulin secretion and reducing glucagon release.
FDA Approves Xigduo XR, a New Dapagliflozin-Metformin Combination for TII
The US Food and Drug Administration (FDA) has approved a once-daily combination of dapagliflozin and metformin hydrochloride extended-release (Xigduo XR, AstraZeneca) for the treatment of adults with type 2 diabetes.
Metformin is best first line of defense against type 2 diabetes
People with type 2 diabetes who take metformin as their first line of defense are less likely to need other medications for blood sugar later on, report researchers from Harvard Medical School.
DiabetesMine – Chewable Glucose Blockers: Legit Science or Snake Oil?
When I hear someone say “complex carbs,” the first images that come to mind are pizza and pasta — and the inevitable post-meal glucose spike and lingering high blood sugars that follow. But a biomedical pharma company in New Hampshire is working on a fix for this — a chewable tablet that looks similar to […]
DiabetesHealth – FDA Approves Once-weekly Trulicity to Treat Type 2 Diabetes
Also known as dulaglutide, Trulicity is a glucagon-like peptide-1 (GLP-1) receptor agonist, which helps normalize blood sugar levels by encouraging the release of insulin, which helps the body better use available blood glucose, while suppressing the stimulation of glucose production.
WSJ – New Implantable Pump Could Cut Diabetes Treatments
A diabetes drug delivered continuously from a small implantable pump resulted in a marked and sustained reduction in blood sugar in patients in two studies, potentially setting the stage for a once-a-year treatment option to manage the disease.
medGadget – ILUVIEN Eye Implant for Diabetic Macular Edema Finally FDA Approved
The FDA, finally, after three rejections, has given approval to pSivida‘s (Watertown, MA) ILUVIEN drug eluting eye implant for treating diabetic macular edema (DME). The device, about the length of, but much narrower than, a grain of rice (3.5 mm x 0.37 mm), is injected intravitreally using a syringe-like device.
FDA Approves Eyla: A New Eye Drug for Diabetic Patients
The decision was made based on two phase 3 clinical trials. These trials included 862 patients and compared Eylea 2 mg given every month, given every two months after five initial monthly injection, and macular laser photocoagulation. In both trials, Eylea demonstrated a significant improvement in diabetic retinopathy in patients with DME after two years […]
FDA Approves Once-Weekly GLP-1 Diabetes Treatment Regimen for T2DM
Dulaglutide is a member of the glucagon-like peptide (GLP-1) receptor agonist class, along with liraglutide, exenatide, and albiglutide. The US Food and Drug Administration (FDA) has approved dulaglutide (Trulicity) as a once a week injection for the treatment of adults with type 2 diabetes.
WebMD – Weekly Diabetes Drugs: FAQs
WebMD asked two doctors and a pharmacist familiar with the new medications to answer some commonly asked questions about the weekly options.
WebMD – Why Statins Might Raise Diabetes Risk
A new study shows that people prescribed statins rather than placebo medication had about a 12% greater risk of getting type 2 diabetes over a 4-year period, and also gained about half a pound in weight on average.
WebMD – Metformin May Affect Thyroid in Some Patients
Metformin, a drug commonly used to treat diabetes, may raise the risk of low levels of thyroid-stimulating hormone (TSH) among patients with an underactive thyroid, a new study suggests.
BattleDiabetes – Hormone-insulin combo more effective for TII than other therapies
A drug that mimics the action of a gut hormone combined with basal insulin is more effective at controlling blood sugar than other diabetes treatments, according to new research published in The Lancet.
Statins And Diabetes: A Clearer Picture Emerges
In recent years, the medical community has become increasingly aware that taking statins can result in slightly higher glucose levels, and this can lead to a diagnosis of diabetes in a small but statistically significant number of people.
No Cancer Link to Actos Long Term in TII Patients
A 10-year analysis of patients with type 2 diabetes treated with pioglitazone (Actos) found no statistically significant increased risk of bladder cancer, either with any exposure or for long duration of use.
DiabetesHealth – Eylea earns FDA approval To Treat Diabetic Macular Edema
The injectable medication, originally prescribed to treat wet macular degeneration ( a disease of the eye that results in a loss of vision at the center of the field of vision when blood vessels abnormally leak fluid into the macula ) was approved for expanded use in late July.